CSPC Pharmaceutical Group (HKSE:01093) 5-Year EBITDA Growth Rate : 14.10% (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is CSPC Pharmaceutical Group 5-Year EBITDA Growth Rate?

CSPC Pharmaceutical Group's EBITDA per Share for the three months ended in Dec. 2023 was HK$0.17.

During the past 12 months, CSPC Pharmaceutical Group's average EBITDA Per Share Growth Rate was -3.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 3.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 14.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 18.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CSPC Pharmaceutical Group was 62.20% per year. The lowest was -52.50% per year. And the median was 19.05% per year.

Competitive Comparison of CSPC Pharmaceutical Group's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSPC Pharmaceutical Group's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's 5-Year EBITDA Growth Rate falls into.

CSPC Pharmaceutical Group 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

CSPC Pharmaceutical Group (HKSE:01093) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

CSPC Pharmaceutical Group 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CSPC Pharmaceutical Group (HKSE:01093) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (HKSE:01093) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CSPCY:USA CHJTF:USA CVG:Germany

Address

No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035

Website

https://www.cspc.com.hk

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC Pharmaceutical Group (HKSE:01093) Headlines

No Headlines